The disposable soma theory posits that aging results from declining selection pressure, allowing antagonistically pleiotropic (AP) genes that boost early fitness to become detrimental later. Beta‑glucan‑induced trained immunity exemplifies thisAP: epigenetic reprogramming of monocytes enhances pathogen resistance in youth but sustains a glycolytic, HIF‑1α‑driven state that fuels chronic inflammation and tissue damage in old age. Recent work shows that mTORC1 activity links metabolic reprogramming to the persistence of trained immunity phenotypes, suggesting a molecular lever that could separate early advantage from late cost.

We hypothesize that transient, partial inhibition of mTORC1 during the induction phase of trained immunity will preserve the protective epigenetic imprint while preventing the metabolic shift that drives inflammaging. Specifically, administering a low dose of rapamycin (or an mTORC1‑selective inhibitor) concurrently with beta‑glucan will maintain H3K27ac marks at promoters of antimicrobial genes (e.g., NOS2, IL1B) but reduce HIF‑1α stabilization and downstream glycolytic flux, thereby limiting the production of lactate‑mediated pro‑inflammatory cytokines (IL‑1β, IL‑6) in aged monocytes.

This hypothesis is testable in murine models. Young mice receive beta‑glucan with or without rapamycin, then are challenged with a lethal dose of Staphylococcus aureus to assess early‑life survival. A separate cohort is allowed to age to 24 months; monocytes are isolated and assayed for (i) chromatin accessibility at trained immunity loci (ATAC‑seq), (ii) glycolytic capacity (ECAR measurements), and (iii) secretion of inflammaging markers after LPS restimulation. If rapamycin preserves early survival without increasing basal ECAR or cytokine release in aged mice, the hypothesis is supported. Conversely, if rapamycin abolishes the early protective effect or fails to attenuate the aged inflammatory phenotype, the hypothesis is falsified.

Mechanistically, mTORC1 couples nutrient sensing to HIF‑1α translation; its inhibition reduces HIF‑1α protein even under normoxic conditions, curbing the glycolytic program that underlies trained immunity’s metabolic memory. By uncoupling the epigenetic and metabolic arms of this program, we intervene not by overriding a putative “aging program” but by adjusting an AP trade‑off that evolution left unoptimized because selection waned after reproduction. This reframes longevity medicine as a negotiation with AP networks: we keep the early‑life advantage while selectively dismantling the late‑life liability.